Phenotype and clinics
-Growth retardation (70% of cases). -Skin abnormalities: hyperpigmentation and/or café au lait spots in 80%.
-Squeletal malformations (60%), particularly radius axis defects (absent or hypoplastic thumb or radius...).
-No immune deficiency (in contrast with most other chromosome instability syndromes).
-Progressive bone marrow failure; mean age of onset of anemia: 8 yrs; diagnosis made before onset of haematologic manifestations in only 30%.
-Other: renal anomalies, hypogonadism, mental impairment, heart defects, and perhaps diabetes mellitus, also occur in 10 to 30% of cases.
Neoplastic risk
-Myelodysplasia (MDS) and acute non lyphocytic leukaemia (ANLL): 10% of cases; i.e. a 15000 fold increased risk of MDS and ANLL has been evaluated in FA, and it has been assumed that 'it is reasonable to regard the Fanconi anemia genotype as 'preleukaemia''; mean age at diagnosis: 15 yrs.
-Hepatocarcinoma (androgen-therapy induced) in 10%; mean age at diagnosis: 16 yrs. -Other cancers in 2-5%: in particular squamous cell carcinoma.
Treatment
Androgens and steroids to improve haematopoietic functions; bone marrow transplantation prevents from terminal pancytopenia, and from ANLL as well.
Prognosis
Mean age at death: 16 years; most patients die from marrow aplasia (haemorrhage, sepsis), and others from malignancies; MDS and ANLL in FA bear a very poor prognosis (median survival of about 6 mths); survival is also poor in the case of a squamous cell carcinoma. 
Cytogenetics

Inborn condition
Cancer cytogenetics
-Various clonal anomalies are found in MDS or ANLL in Fanconi anaemia patients, such as the classical -5/del(5q), and -7/del(7q), found in 10 % of cases; telomeres appear to be non randomly involved in FA's clonal anomalies. 
Other findings
Genes involved and Proteins
Complementation groups: 4 well known complementation groups: group A (gene FA1 in 16q24, perhaps another gene 20q13), group B, group C (gene FACC in 9q22), group D (gene FAD in 3p24 has sometimes been located in 11q23); a fifth group, group E, may, per se, be heterogenous; however, the different complementation groups display similar phenotypes, and genes may therefore be functionally related (recently was found that FA1 and FACC form heterodimers).
FA1
Location: 16q24 Protein Expression: wide. Localisation: mostly cytoplasmic. Function: binds to the protein encoded by FACC (see below), the dimer being found in the cytoplasm and the nucleus. Homology: no known homology.
Mutations
Germinal: various nucleotide substitutions, deletions, or insertions.
FACC
Location: in 9q22
Protein Expression: wide. Localisation: cytoplasmic when unbound. Function: peak expression during the G2/M transition; binds to cdc2 (mitotic cyclin-dependent kinase); probably involved in basic aspect(s) of the cell protection against DNA damages: role in the cell cycle regulation and/or in DNA repair and/or in the prevention of cellular apoptosis; binds to FAA, the protein encoded by FA1 (see above), the dimer being found in the cytoplasm and the nucleus. Homology: no known homology.
Mutations
Germinal: nucleotide substitutions.
FAD
Location: 3p24
To be noted Clinical diagnosis may, in certain cases, be very difficult; cytogenetic ascertainment is then particularly useful; however, cytogenetic diagnosis may also, at times, be very uncertain; this is a great problem when bone marrow engraftment has been decided in a pancytopenic patient: if this patient has FA, bone marrow conditioning must be very mild, as FA cells are very clastogen sensitive. FA patients (i.e. patients with defective alleles) may have, in a percentage of cells, a somatic reversion (by revert mutation towards wild-type gene); such a phenomenon is also known in Bloom syndrome, another chromosome instability syndrome.
